Globally, the human capital management market is expected to grow with a CAGR of 8.5% during the forecast period from 2022 to 2030, starting from US$ 17.95 Bn in 2021. The market is driven by the increase demand among organizations to streamline the resource management, payroll, vendor management and other HR functions.
The life science instrumentation market is set to reach US$ 107,344.2 Mn by 2030 from US$ 68,336.6 Mn in 2021 showcasing moderate growth at a compounded annual growth rate (CAGR) of 6.5% during the forecast period from 2022 to 2030. Technological advancement in life science instruments and stringent healthcare norms pertaining to food and drug manufacturing processes drive market growth for life science instrumentation techniques.
Companies in the life sciences are advancing in their adoption and use of digital and analytics. Yet, by heeding the lessons of recent years, they may move further and more quickly. Notwithstanding efforts over the past five years, life sciences businesses continue to lag cross-industry leaders in digital maturity by a ratio of two to three in every critical dimension—strategy, culture, organization, and capabilities—with no obvious signs of closing the gap.
Derisking drug discovery, speeding clinical trials, and reimagining engagement with HCPs are the greatest prospects that DnA could assist to realize. As a result, numerous industry leaders are adopting DnA into early-stage drug discovery and clinical development to shorten timeframes and increase the likelihood of success. In addition, market leaders are reimagining their connections with healthcare practitioners and patients in order to offer enhanced and individualized experiences and improve treatment outcomes.
The life sciences are progressively adopting cloud technology to accelerate tech-enabled business changes; by 2021, more than 80 percent of the top 20 global pharma and medtech enterprises will be cloud-based. In addition, businesses are increasingly utilizing the cloud to shift IT infrastructure management and to cover gaps in their software development and analytics skills by purchasing software as a service as opposed to building and maintaining it themselves.
Despite the widespread media interest, longer-term bets such as quantum technologies, Web3, and immersive reality account for just approximately 15% of life sciences technology investments. With a combination of Al and ML, cloud computing, quantum technologies, and bioengineering, for instance, life sciences firms may speed drug development, produce more tailored medicines, and optimize treatment regimens for patients.
Acute Market Reports is a market research and consulting company with a focus on the life sciences industry. Acute Market Reports' futuristic research model benefits our clients by enabling them to make timely, thoughtful business decisions. To deliver cutting-edge strategic research solutions to our international customers, we work with a wide range of industry participants.
